Regenxbio Inc (NASDAQ:RGNX) SVP Patrick J. Christmas sold 5,000 shares of the firm’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $65.96, for a total transaction of $329,800.00. Following the sale, the senior vice president now directly owns 22,669 shares of the company’s stock, valued at $1,495,247.24. The transaction was disclosed in a document filed with the SEC, which is available at this link.

NASDAQ RGNX opened at $66.15 on Friday. Regenxbio Inc has a 12 month low of $19.45 and a 12 month high of $85.10. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 34.14, a P/E/G ratio of 8.41 and a beta of -1.16.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported $0.30 EPS for the quarter, missing the Zacks’ consensus estimate of $1.23 by ($0.93). Regenxbio had a net margin of 44.44% and a return on equity of 28.70%. The company had revenue of $40.03 million for the quarter, compared to the consensus estimate of $100.00 million. equities research analysts predict that Regenxbio Inc will post 2.63 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Amalgamated Bank bought a new position in Regenxbio during the 2nd quarter valued at $332,000. Fred Alger Management Inc. bought a new position in Regenxbio during the 2nd quarter valued at $933,000. UBS Group AG boosted its stake in Regenxbio by 71.2% during the 1st quarter. UBS Group AG now owns 43,251 shares of the biotechnology company’s stock valued at $1,291,000 after acquiring an additional 17,994 shares during the last quarter. Redmile Group LLC boosted its stake in Regenxbio by 49.5% during the 1st quarter. Redmile Group LLC now owns 2,130,972 shares of the biotechnology company’s stock valued at $63,610,000 after acquiring an additional 705,700 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in Regenxbio during the 1st quarter valued at $233,000. Hedge funds and other institutional investors own 78.29% of the company’s stock.

RGNX has been the subject of a number of recent analyst reports. Bank of America lowered shares of Regenxbio from a “buy” rating to a “neutral” rating and raised their price target for the company from $64.00 to $80.00 in a report on Monday, July 23rd. Chardan Capital raised their price target on shares of Regenxbio from $90.00 to $130.00 and gave the company a “buy” rating in a report on Monday, July 16th. BidaskClub raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Friday, June 1st. Morgan Stanley raised their price target on shares of Regenxbio from $37.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, July 13th. Finally, TheStreet raised shares of Regenxbio from a “d+” rating to a “c” rating in a report on Friday, May 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $74.79.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

See Also: Should I invest in “strong buy” stocks?

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.